ReviewEuropean journal of medical research2010
Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) pneumonia: linezolid or vancomycin? - Comparison of pharmacology and clinical efficacy.
Review in European journal of medical research, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02019420 (A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 3 Randomized Double-blind Study Comparing TR-701 FA and Linezolid in Ventilated Gram-positive Nosocomial Pneumonia
Who cites it
27 citing papers in PubMed, 55 citations in OpenAlex.
- Article
- Review
- Methicillin-resistantCurrent pharmaceutical biotechnology · 2025Review
- Assessment of the pattern of antibiotic resistance among microorganisms isolated from the culture medium prepared from hospitalized patients: A retrospective study.Journal of family medicine and primary care · 2024Article
- Neonatal methicillin-resistantWorld journal of clinical cases · 2023Article
- Human Defensins: A Novel Approach in the Fight against Skin ColonizingAntibiotics (Basel, Switzerland) · 2020Review
- Staphylococcal-Produced Bacteriocins and Antimicrobial Peptides: Their Potential as Alternative Treatments forAntibiotics (Basel, Switzerland) · 2020Review
- Methods Used for the Eradication of Staphylococcal Biofilms.Antibiotics (Basel, Switzerland) · 2019Review
- Zinc-doped Prussian blue enhances photothermal clearance of Staphylococcus aureus and promotes tissue repair in infected wounds.Nature communications · 2019Article
- Linezolid Attenuates Lethal Lung Damage during Postinfluenza Methicillin-Resistant Staphylococcus aureus Pneumonia.Infection and immunity · 2019Article
- A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators.Infectious diseases and therapy · 2019Article
- Evidence from an In Vitro Study: Is Oxacillin Plus Vancomycin a Better Choice for Heteroresistant Vancomycin-Intermediate Staphylococcus aureus?Infectious diseases and therapy · 2019Article
- Linezolid use in German acute care hospitals: results from two consecutive national point prevalence surveys.Antimicrobial resistance and infection control · 2019Article
- Management of methicillin-resistantCurrent trends in microbiology · 2018Article
- Treatment of MRSA pneumonia: Clinical and economic comparison of linezolid vs. vancomycin - a retrospective analysis of medical charts and re-imbursement data of real-life patient populations.GMS infectious diseases · 2017Article
- Experience with ceftaroline for treatment of methicillin-resistantJournal of community hospital internal medicine perspectives · 2017Article
- Top Guns: The "Maverick" and "Goose" of Empiric Therapy.Surgical infections · 2016Article
- Methicillin-resistant Staphylococcus aureus nosocomial pneumonia: role of linezolid in the People's Republic of China.ClinicoEconomics and outcomes research : CEOR · 2016Review
- Vancomycin-Associated Nephrotoxicity: The Obesity Factor.Surgical infections · 2015Article
- Role of Interleukin-12 in Protection against Pulmonary Infection with Methicillin-Resistant Staphylococcus aureus.Antimicrobial agents and chemotherapy · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The incidence of nosocomial pneumonia involving methicillin-resistant Staphylococcus aureus strains (MRSA) is on the rise worldwide. For years, vancomycin has been used as the drug of choice in the treatment of MRSA infections and was recommended as such by clinical guidelines. There is growing evidence that vancomycin, despite low resistance rates is a suboptimal therapeutic option in critically ill patients, particularly in patients with pneumonia. Disadvantages of vancomycin are i) slow bactericide action, ii) poor penetration into pulmonary tissue, iii) the globally slowly increasing vancomycin MICs ("creep") that result in increased clinical failure despite being susceptible according to defined break points and iv) nephrotoxicity. In contrast to other novel antibiotics with MRSA activity, Linezolid is currently approved for the treatment of nosocomial pneumonia in the USA and Europe. Several studies have compared vancomycin with linezolid for nosocomial pneumonia with conflicting results. This review compares both substances regarding pharmacodynamics, resistance, safety and clinical efficacy and discusses preliminary data of the ZEPHyR study. This study compared linezolid versus vancomycin in patients with proven MRSA pneumonia and was the largest trial ever conducted in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.